Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Stephan C. Schürer"'
Autor:
Caty Chung, Nicholas A. Clark, Michele Forlin, John Paul Turner, Christopher C. Mader, Mehdi Fazel, Sherry L. Jenkins, Amar Koleti, Naim Al Mahi, John F. Reichard, Tanya T. Kelley, Alessandro D'Urso, Kathleen M. Jagodnik, Dusica Vidovic, Mario Medvedovic, Marcin Pilarczyk, Vasileios Stathias, Behrouz Shamsaei, Lily Wang, Wen Niu, Avi Ma'ayan, Stephan C. Schürer, Daniel J. Cooper, Denis Torre, Bryce K. Allen, Raymond Terryn, Juozas Vasiliauskas, Jarek Meller, Ajay Pillai
Publikováno v:
Nucleic Acids Research
The Library of Integrated Network-based Cellular Signatures (LINCS) program is a national consortium funded by the NIH to generate a diverse and extensive reference library of cell-based perturbation-response signatures, along with novel data analyti
Autor:
José L. Medina-Franco, Fernanda Borges, Stephan C. Schürer, Aminael Sánchez-Rodríguez, Yunierkis Pérez-Castillo, Eduardo Tejera, Maykel Cruz-Monteagudo
Publikováno v:
Drug Discovery Today. 22:994-1007
Current advances in systems biology suggest a new change of paradigm reinforcing the holistic nature of the drug discovery process. According to the principles of systems biology, a simple drug perturbing a network of targets can trigger complex reac
Autor:
Nagi G. Ayad, David J. Robbins, Vasileios Stathias, Stephan C. Schürer, Marie E. Maloof, Jennifer Clarke, Anthony J. Capobianco, Bryce K. Allen, Emily F. Winterbottom, Dusica Vidovic
Publikováno v:
Journal of Cellular Biochemistry. 116:351-363
There is an urgent need to identify novel therapies for glioblastoma (GBM) as most therapies are ineffective. A first step in this process is to identify and validate targets for therapeutic intervention. Epigenetic modulators have emerged as attract
Autor:
Stephan C. Schürer, Saurabh Mehta, Nagi G. Ayad, Stewart W. J. Ember, Bryce K. Allen, Ernst Schönbrunn
Publikováno v:
Scientific Reports
Inhibition of cancer-promoting kinases is an established therapeutic strategy for the treatment of many cancers, although resistance to kinase inhibitors is common. One way to overcome resistance is to target orthogonal cancer-promoting pathways. Bro
Publikováno v:
Cancer Research. 77:416-416
The goal of our study was to identify patient-specific gene expression networks from Glioblastoma Patient-Derived Xenografts (PDXs) and determine novel therapeutic compound combinations using those networks. Glioblastoma is the most common malignant
Publikováno v:
PeerJ, Vol 2, p e524 (2014)
PeerJ
PeerJ
Bioinformatics and computer aided drug design rely on the curation of a large number of protocols for biological assays that measure the ability of potential drugs to achieve a therapeutic eff ect. These assay protocols are generally published by sci
Autor:
Caroline E. Shamu, Christopher C. Mader, Gabriel F. Berriz, Sean D. Erickson, David Wrobel, Cyril H. Benes, Nakul Datar, Dusica Vidovic, Caty Chung, Amar Koleti, Ajay S. Pillai, Uma D. Vempati, Stephan C. Schürer, Jeremy L. Muhlich, Aravind Subramanian
Publikováno v:
J Biomol Screen
The National Institutes of Health Library of Integrated Network-based Cellular Signatures (LINCS) program is generating extensive multidimensional data sets, including biochemical, genome-wide transcriptional, and phenotypic cellular response signatu
Autor:
Eric S. Dawson, Anna Waller, Mark R. Southern, Thomas D.Y. Chung, Jeremy J. Yang, Stephan C. Schürer, Tudor I. Oprea, Noel Southall, Steve Brudz, David L. Lahr, Andrea de Souza, Rajarshi Guha, Simon Chatwin, Paul A. Clemons, Joshua A. Bittker, Uma D. Vempati
Publikováno v:
Journal of biomolecular screening. 19(5)
Recent industry–academic partnerships involve collaboration among disciplines, locations, and organizations using publicly funded “open-access” and proprietary commercial data sources. These require the effective integration of chemical and bio
Autor:
Ahsan Mir, Uma D. Vempati, Saminda Abeyruwan, Kunie Sakurai, Stephan C. Schürer, Caty Chung, Magdalena J. Przydzial, Vance Lemmon, Ubbo Visser
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 11, p e49198 (2012)
PLoS ONE, Vol 7, Iss 11, p e49198 (2012)
Huge amounts of high-throughput screening (HTS) data for probe and drug development projects are being generated in the pharmaceutical industry and more recently in the public sector. The resulting experimental datasets are increasingly being dissemi
Publikováno v:
Cancer Research. 76:775-775
The purpose of this study is to leverage the large number of perturbation signatures from the NIH Library of Integrative Network-based Cellular Signatures (LINCS) and integrate them with patient data from The Cancer Genome Atlas (TCGA) and PubChem bi